Preclinical studies: how much can we rely on?

J. Rothstein
DOI: https://doi.org/10.1080/17434470410020012
2004-09-01
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
Abstract:Preclinical research provides a foundation for our goal of choosing new amyotrophic lateral sclerosis (ALS) therapeutics and how to use those drugs in planning and executing human clinical trials. This paper attempts to digest what has been learned from preclinical studies over the past seven years, especially since the use of transgenic rodents expressing mutant superoxide dismutase-1 (SOD1). However, it is important to review what has been done over the past decade in terms of ALS modern therapeutics, because I would argue that well though out use of preclinical tools began in the late 1980s and early 1990s when model systems were first developed. Model systems are fundamental, but with the strong caveat that disease models only approximate to aspects of the complex human disease, and as such have obvious shortcomings. The real test is clinical trials in human disease, but these tools are necessary to focus our decision-making.
What problem does this paper attempt to address?